GET THE APP

Chronic Actinic Damage in Pigmented and Depigmented Skin of Hispa
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 1478 350008

Research Article - (2012) Volume 3, Issue 4

Chronic Actinic Damage in Pigmented and Depigmented Skin of Hispanic Patients with Vitiligo: Clinical and Histological Differences

Maria Teresa Garcia-Romero1*, Ochoa-Sánchez Patricia Esmeralda1, Díaz-Lozano Marisol2, Toussaint-Caire Sonia2 and Lacy-Niebla Rosa Maria1
1Departamento de Dermatología, Hospital General, Dr. Manuel Gea González, México D.F., Mexico
2Sección de Dermatopatología, Hospital General, Dr. Manuel Gea González, México D.F., Mexico
*Corresponding Author: Maria Teresa Garcia-Romero, Hospital General, Dr. Manuel Gea González, Calzada De Tlalpan No. 4800, Seccion XVI, DF CP 14080, Mexico, Tel: (52) 5540003000, Fax: (52) 5540003087 Email:

Abstract

Vitiligo is a common depigmentary disorder, with loss of epidermal Melanocytes as its hallmark. This absence of melanin hypothetically makes skin more susceptible to Chronic Actinic Damage (CAD) and skin cancer development. However, various studies have shown no increased incidence of skin cancer and some point to decreased actinic damage in skin with vitiligo. We studied 14 patients with vitiligo and analyzed clinical and histological markers of chronic actinic damage both in depigmented skin with vitiligo and in normal skin. We found fewer markers of clinical CAD in depigmented skin than in normally pigmented skin. When we analyzed histological, we found that in most patient’s depigmented skin had increased hyperkeratosis, which is a previously reported finding, as well as atrophy, elastosis and telangiectasias. There are various hypotheses to explain these findings. Further studies are needed to establish if vitiligo provides protection against CAD, either by structural changes or a better immunosurveillance process in the skin affected by it.

<

Keywords: Chronic Actinic Damage (CAD); Non-Melanoma Skin Cancer (NMSC); Vitiligo; Depigmented skin; Pigmented skin

Introduction

Vitiligo is the most common pigmentary disorder, with a prevalence of 0.5-1% in the world population. Almost half of patients present with the disease are below 20 years of age. Both sexes are affected equally and apparently there are no differences in prevalence according to skin type and race [1].

The pathologic hallmark is a loss of epidermal melanocytes. An inflammatory infiltrate can be found or not, especially at the margins of the depigmented area. The pathophysiology is still debated, but involves immune factors, oxidative stress or a sympathetic neurogenic disturbance. Some genes have been associated with vitiligo, either in isolation or as part of an autoimmune diathesis [1].

Melanocytes have several functions, among which is the absorption of Ultraviolet Radiation (UVR). The skin is the main barrier to external environment and relies on melanocytes to provide photoprotection and thermoregulation by producing melanin. Pigmentation protects skin by straightforward shielding by melanin, but also because melanocytes survive considerable oxidative stress. The degree of pigment production manifests as skin phototype, and is the most useful predictor of skin cancer risk [2]. So the degree of protection against Chronic Actinic Damage (CAD) depends on the cumulative dose of sunlight versus the efficacy of the anti-oxidant defense mechanisms of the skin. This protective role of melanin is supported by the lower susceptibility to actinic damage and skin cancer in darker phototypes compared to lighter ones [2-5]. This is further supported in African albinos who experience high incidences of actinic damage and Non- Melanoma Skin Cancer (NMSC) during their entire lifetime [6].

Skin with Chronic Actinic Damage (CAD) is characterized by wrinkling, telangiectasias, mottled pigmentation, atrophy, laxity, pseudoscars, purpura and premalignant or malignant neoplasms. Histological changes of chronic epidermal actinic damage are variable thickness of the stratum corneum, with areas of severe hyperplasia besides atrophy, some degree of nuclear atypia in melanocytes and keratinocytes [7-10]. There are different qualitative and quantitative methods for determining actinic damage but no standardized, reproducible method has been proposed [11-13].

Since patients with vitiligo have areas without melanocytes and consequently without pigment, we would expect these persons to have an increased risk of CAD and NMSC. However, several reports point to the exact opposite. Several studies have shown low incidence of skin cancer in patients with vitiligo [14,15]. Moreover, a lot of patients with vitiligo have used phototherapy or photochemotherapy for their disease, and one would expect this group to have a much higher incidence of NMSC. But proportionally to the high prevalence of vitiligo, there are few reports of increased skin cancer in patients with vitiligo even after psoralen and UVA (PUVA) therapy [16-25]. In a recent study, no increased risk for photosensitivity disorders and no signs of increased CAD in the skin of patients with vitiligo were found [14].

One hypothesis for these findings is that patients with vitiligo perform better sun protection measures due to increased risk of burning, but even in remote areas where patients are not using sunblocking substances, a lack of actinic keratosis or NMSC has been reported. Another study proposed that the stratum corneum in the skin with vitiligo was thicker and this could protect the depigmented skin from UV radiation [26].

All of these studies trying to establish a connection between depigmented skin with vitiligo and CAD have been done in caucasian populations. In this study, we examined a group of hispanic patients with skin phototypes III-V and vitiligo to describe clinical and histological markers of CAD in pigmented and depigmented skin.

Materials and Methods

We selected 14 patients (7 males and 7 females) with vitiligo from our outpatient dermatology clinic. All patients authorized the study and signed a consent form. All patients were subjected to a complete physical examination and clinical markers of CAD were intentionally searched for and evaluated (Table 1). Two 4-mm punch biopsies were taken under local anaesthesia from sun exposed skin; one biopsy was from depigmented skin and the other one from normal skin. Both biopsies were processed, stained with hematoxilin and eosin and silver stain and reviewed by a dermatopathologist, who intentionally searched for and evaluated histopathological signs of CAD (Table 2).

Clinical marker Score
Xerosis 1
Freckles 1
Lentigines 1
Guttate hipomelanosis 1
Persistent hyperpigmentation 1
Fine wrinkles 1
Deep wrinkles 1
Stellate pseudoscars 1
Elastosis 1
Loss of elasticity 1
Telangiectasias 1
Venous lakes 1
Purpura 1
Comedones (Favre-Racouchot) 1
Actinic keratoses 10
Non melanoma skin cancer 10
Melanoma 10
0 points=no photodamage, 1-5 points=mild photodamage, 6-10 points=moderate actinic damage, ≥ 11 points=severe actinic damage

Table 1: Clinical markers of Chronic Actinic Damage (CAD).

Histological marker Score
Hyperkeratosis 1
Acanthosis 1
Lentigines 1
Epidermal atrophy 1
Epidermal hyperpigmentation 1
Fibroblast hyperplasia 1
Nodular elastosis 1
Diffuse elastosis 1
Ephelides 1
Lentigines 1
Telangiectasias 1
Venous lakes 1
Purpura 1
Comedones 1
Actinic keratoses 10
Non melanoma skin cancer 10
Melanoma 10
0 points=no actinic damage, 1-5 points=mild actinic damage, 6-10 points=moderate actinic damage, ≥ 11 points=severe actinic damage

Table 2: Histopathological markers of Chronic Actinic Damage (CAD).

According to the clinical and histopathological signs that were evaluated, each patient received a score and was categorized in one of four grades of CAD depending on the score (0 points=none, 1-5 points=mild, 6-10 points=moderate, ≥ 11 points=severe).

Results

The patients’ demographic data are shown in Table 3. The mean age was 48.4 years. All patients had skin phototypes III to IV. The mean duration of the disease was 21.1 years. None of the patients had a history of sunburns.

  n (%)
Sex      Female      Male   7 (50%) 7 (50%)
Age (years)      20-29        30-39      40-49      50-59      +60   2 (14.2%) 3 (21.4%) 3 (21.4%) 3 (21.4%) 3 (21.4%)
Phototype      III      IV      V   2 (14.2%) 9 (64.2%) 3 (21.4%)
Evolution of vitiligo (years)      5-9      10-15      16-20      21-25      26-30   1 (7%) 5 (35.7%) 3 (21.4%) 2 (14.2%) 3 (21.4%)
History of sunburns      Yes      No   2 (14.2%) 12 (86%)
History of photosensitivity reactions      Yes      No   1 (7%) 13 (93%)

Table 3: Demographic characteristics of the patients with vitiligo.

Clinical chronic actinic damage (CAD)

In normally pigmented skin, 1 patient (7%) had no markers of, 11 (78%) had mild and 2 (14%) had moderate damage; average score was 4 points (56/14).

In depigmented skin, 2 patients (14%) had no markers of, 11 (78%) had mild, and 1 (7%) had moderate damage; average was 1.85 points (26/14).

In Figure 1, we can see the distribution of the score for clinical CAD in each patient’s normally pigmented skin compared with depigmented skin. In Figure 2, we can see the distribution of the summed score for all patients in both types of skin.

clinical-experimental-dermatology-pigmented-skin

Figure 1: Comparison between each patient’s degree of clinical chronic actinic damage in depigmented skin with vitiligo vs normally pigmented skin.

clinical-experimental-dermatology-chronic-actinic-damage

Figure 2: Distribution of the overall clinical chronic actinic damage score found on all patients, comparing depigmented skin with vitiligo vs normally pigmented skin.

Histological chronic actinic damage (CAD)

In normally pigmented skin, 7 patients (50%) had no markers of and 7 (50%) had mild damage; average was 0.64 points (9/14).

In depigmented skin, 4 patients (28%) had no markers of and the rest (72%) had mild damage; average was 1.85 points (20/14).

In Figure 3, we can see the distribution of the score for histological chronic actinic damage in each patient’s normally pigmented skin vs depigmented skin. In Figure 4, we can see the distribution of the summed score for all patients in both types of skin.

clinical-experimental-dermatology-histological-chronic

Figure 3: Comparison between each patient’s degree of histological chronic actinic damage in biopsies of depigmented skin with vitiligo vs normally pigmented skin.

clinical-experimental-dermatology-actinic-damage-score

Figure 4: Distribution of the overall histological chronic actinic damage score found on all patients, comparing depigmented skin with vitiligo vs normally pigmented skin.

Discussion

In this study, we analyzed clinical and histological findings suggestive of CAD in patients with Fitzpatrick´s skin phototype III to IV who also had depigmented skin affected by vitiligo. We found several interesting results.

First, there were fewer findings of clinical CAD in depigmented skin with vitiligo than in normally pigmented skin (Figure 5). This is compatible with previous reports where large cohorts of patients with vitiligo have been found to have a low incidence of skin cancer. Calanchini-Postizzi and Frenk studied 23 patients with longstanding vitiligo, and only found 3 actinic keratoses in sun-exposed vitiligo skin [15]. Similarly, there are very few reports of patients with vitiligo developing a squamous cell carcinoma after PUVA therapy [16-19] and one developing a keratoacanthoma after therapy with narrow band UVB (NB-UVB) [25].

clinical-experimental-dermatology-coarse-wrinkling

Figure 5: Chronic actinic damage is clinically more evident in pigmented skin: atrophy, fine and coarse wrinkling.

Large cohort studies have followed patients with vitiligo and phototherapy and have found no evidence of NMSC or melanoma [20-23]. The largest series up to now is by Westerhof and Schallreuter [24], who studied 2500 patients with vitiligo without finding any cases of skin cancer.

One of the hypothesis that has been proposed for a lower incidence of CAD is that patients with vitiligo perform better photoprotection measures that healthy individuals and this could be the reason of lower actinic damage manifestations [26]. But patients with vitiligo in Tanzania who cannot use sunblocking substances or physical measures do not have any evidence of actinic keratosis or NMSC, as Nordlund recently reported [27].

When we analyzed histological signs, we found that in most patients, the depigmented skin with vitiligo had slightly more markers of CAD than normal skin. The change that predominated in the biopsies of skin with vitiligo while none of the biopsies of normally pigmented skin had, was hyperkeratosis, which is a previously reported finding (Figures 6 and 7). Everett [28] observed hyperkeratosis of the stratum corneum in the skin with vitiligo, and proposed that this could protect the depigmented skin from UV radiation [28]; nonetheless, the photoprotecting capacity by unit of thickness was lower than in normal skin [26].

clinical-experimental-dermatology-histological-markers

Figure 6: Biopsy of pigmented skin. No histological markers of chronic actinic damage.

clinical-experimental-dermatology-depigmented-skin

Figure 7: Biopsy of the same patient, depigmented skin. Marked hyperkeratosis and elastosis.

Besides hyperkeratosis, the other markers that were found to be more frequent in the biopsies of skin with vitiligo were: atrophy, elastosis and telangiectasias. However, our group of patients is not large and so the differences detected in 1 or 2 patients are not significant.

Previous studies have found decreased signs of CAD in skin with vitiligo as Schallreuter et al. [14], who found no difference in histological signs of CAD in biopsies of sunexposed normally pigmented and depigmented skin, although skin with vitiligo had persistent oxidative stress by millimolar amounts of H2O2. Their results support that individuals suffering from vitiligo must be protected against CAD by mechanisms other than melanin and stratum corneum thickening [14].

Calanchini-Postizzi and Frenk [15] performed a study comparing skin with vitiligo and normal skin, and found no evidence of an increase in CAD in the skin without melanin.

Another comparison between patients with vitiligo and healthy controls reported fewer sunburn cells in the former group [29].

Schallreuter et al. studied the expression of epidermal p53 in patients with vitiligo and found an increased upregulation of the wild type p53 protein in comparison with healthy controls. This increase in this tumor suppressing gene could play a role in the low incidence of skin cancer in these patients [30].

This is the first study that has analyzed both clinical and histological CAD in hispanic patients, who have darker phototypes, affected by vitiligo. This is an observational, descriptive study with a limited number of patients, so a statistical analysis is impossible. It is difficult to reach conclusions based on the differences detected in our study. However, we can learn from these findings that show a distinct trend which has been described before.

Our findings as well as previously reported analyses all together show evidence that there are several factors playing a role in possibly a better immunosurveillance in depigmented skin with vitiligo or better DNA-repairing mechanisms. Further research in the subject is needed as the etiology of these apparently contradictory findings could be of use in developing new immunotherapy options for melanoma.

References

  1. Yaar M (2007) The Chronic Effects of Ultraviolet Radiation on the Skin: Photoaging. In: Lim HW, Hönigsmann H, Hawk JLM (Eds) Photodermatology. Inc. Ed., Informa Healthcare USA, 91-106.
  2. Domínguez-Soto L, Lacy-Niebla RM (1994) Fotodermatosis por Daño Directo. En Fotodermatosis-1. Cuadernos de Actualización Dermatológica- 1: 2. Comarketing Ed. S.A. de C.V. México, D.F.
  3. Fisher GJ, Kang S, Varani J, Bata-Csorgo Z, Wan Y, et al. (2002) Mechanisms of Photoaging and Chronological Skin Aging. Arch Dermatol 138: 1462-1470.
  4. . Halder RM, Bridgeman-Shah S (1995) Skin cancer in African Americans. Cancer 75: 667-673.
  5. Gronskov K, Ek J, Brondum-Nielsen K (2007) Oculocutaneous albinism. Orphanet J Rare Dis 2: 43.
  6. Trautinger F (2001) Mechanisms of photodamage of the skin and its functional consequences for skin ageing. Clin Exp Dermatol 26: 573-577.
  7. Gilchrest BA (1979) Relationship between actinic damage and chronologic aging in keratinocyte cultures of human skin. J Invest Dermatol 72: 219-223.
  8. Bhattacharyya TK, Thomas JR (2004) Histomorphologic changes in aging skin: observations in the CBA mouse model. Arch Facial Plast Surg 6: 21-25.
  9. Richard S, de Rigal J, de Lacharriere O, Berardesca E, Leveque JL (1994) Noninvasive measurement of the effect of lifetime exposure to the sun on the aged skin. Photodermatol Photoimmunol Photomed 10: 164-169.
  10. Griffiths CE, Wang TS, Hamilton TA, Voorhees JJ, Ellis CN (1992) A photonumeric scale for the assessment of cutaneous photodamage. Arch Dermatol 128: 347-351.
  11. Griffiths CE (1992) The clinical identification and quantification of photodamage. Br J Dermatol 127: 37-42.
  12. Marks R, Edwards C (1992) The measurement of photodamage. Br J Dermatol 127: 7-13.
  13. Schallreuter KU, Tobin DJ, Panske A (2002) Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with vitiligo. Dermatology 204: 194-201.
  14. Calanchini-Postizzi E, Frenk E (1987) Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. Dermatologica 174: 266-271.
  15. Seo SL, Kim IH (2001) Squamous cell carcinoma in a patient with generalized vitiligo. J Am Acad Dermatol 45: S227-S229.
  16. Akimoto S, Suzuki Y, Ishikawa O (2000) Multiple actinic keratoses and squamous cell carcinomas on the sun-exposed areas of widespread vitiligo. Br J Dermatol 142: 824-825.
  17. Takeda H, Mitsuhashi Y, Kondo S (1998) Multiple squamous cell carcinomas in situ in vitiligo lesions after long-term PUVA therapy. J Am Acad Dermatol 38: 268-270.
  18. Park HS, Lee YS, Chun DK (2003) Squamous cell carcinoma in vitiligo lesion after long-term PUVA therapy. J Eur Acad Dermatol Venereol 17: 578-580.
  19. Wildfang IL, Jacobsen FK, Thestrup-Pedersen K (1992) PUVA treatment of vitiligo: a retrospective study of 59 patients. Acta Derm Venereol 72: 305-306.
  20. Harrist TJ, Pathak MA, Mosher DB, Fitzpatrick TB (1984) Chronic cutaneous effects of long-term psoralen and ultraviolet radiation therapy in patients with vitiligo. Natl Caner Inst Monogr 66: 191-196.
  21. Halder RM, Battle EF, Smith EM (1995) Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. Arch Dermatol 131: 734-735.
  22. Hexsel CL, Eide MJ, Johnson CC, Krajenta R, Jacobsen G, et al. (2009) Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. J Am Acad Dermatol 60: 929-933.
  23. Westerhof W, Schallreuter KU (1997) PUVA for vitiligo and skin cancer. Clin Exp Dermatol 22: 54.
  24. Brazzelli V, Barbagallo T, Prestinari F, Vassallo C, Agozzino M, et al. (2006) Keratoacanthoma in vitiligo lesion after UVB narrowband phototherapy. Photodermatol Photoimmunol Photomed 22: 211-213.
  25. Brazzelli V, Barbagallo T, Prestinari F, Vassallo C, Agozzino M, et al. (2006) Keratoacanthoma in vitiligo lesion after UVB narrowband phototherapy. Photodermatol Photoimmunol Photomed 22: 211-213.
  26. Nordlund JJ (2000) A visit to Eden: living and working at the regional dermatology training center in Tanzania. J Am Acad Dermatol 43: 1101-1108.
  27. Everett MA (1961) Protection from sunlight in vitiligo. Arch Dermatol 84: 997-998.
  28. Gniadecka M, Wulf HC, Mortensen NN, Poulsen T (1996) Photoprotection in vitiligo and normal skin. A quantitative assessment of the role of stratum corneum, viable epidermis and pigmentation. Acta Derm Venereol 76: 429-432.
  29. Nordlund JJ (2000) A visit to Eden: living and working at the regional dermatology training center in Tanzania. J Am Acad Dermatol 43: 1101-1108.
Citation: Garcia-Romero MT, Esmeralda OSP, Marisol DL, Sonia TC, Maria LNR (2012) Chronic Actinic Damage in Pigmented and Depigmented Skin of Hispanic Patients with Vitiligo: Clinical and Histological Differences. J Clin Exp Dermatol Res 3:154.

Copyright: © 2012 Garcia-Romero MT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top
https://www.olimpbase.org/1937/